Immunostimulatory compositions and methods

a composition and immunomodulatory technology, applied in the field of immunomodulatory compositions and methods, can solve the problems of limited efficacy of these approaches, less than satisfactory clinical responses, adverse side effects, etc., and achieve the effect of enhancing the immune respons

Active Publication Date: 2007-08-09
UNIV OF LOUISVILLE RES FOUND INC +1
View PDF6 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cancer treatments involving surgery, chemotherapy and radiotherapy are commonly used, but these approaches lack tumor specificity, resulting in adverse side effects and less than satisfactory clinical responses.
The limited efficacy of these approaches may stem from the ability of progressing tumors to control immune responses using one or several immune evasion strategies, or due to immunosuppressive mechanisms, inefficient presentation of TAAs, or lack of potent activation of DC, Teff cells, and NK cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunostimulatory compositions and methods
  • Immunostimulatory compositions and methods
  • Immunostimulatory compositions and methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

CSA-4-1BBL Augments Alloantigen-Driven Responses

[0193] As discussed above, 4-1BBL plays an important role in the regulation of adaptive and innate immune responses. 4-1BBL serves as a costimulatory molecule for the activation of CD4+ and CD8+ T cells, NK cells, and DCs and inhibits the suppressive function of Treg cells. Therefore, this molecule can serve as a specific adjuvant for the generation of an effective tumor response for cancer therapy.

[0194] The CSA-4-1BBL fusion protein forms tetrameric / oligomeric structure due to the presence of the core streptavidin moiety, and is a soluble molecule. The immunostimulatory activity of CSA-4-1BBL on T cell responses was demonstrated using allogeneic mixed lymphocytes reactions (MLR) as follows.

[0195] C57BL / 6 mice lymph node cells were used as responders against BALB / c irradiated splenocytes in the presence or absence of CSA-4-1BBL. Cultures were labeled with [3H]thymidine for the last 18 hours of the culture period and proliferation w...

example 2

CSA-4-1BBL Enhances T cell Proliferation

[0196] To assess the relative activity of the 4-1-BBL fusion protein to a monoclonal antibody against 4-1BB, CD4+ and CD8+ T cells sorted by flow cytometry were polyclonally stimulated with a suboptimum concentration of anti-CD3 antibody in the presence of various amounts of 4-1BBL fusion protein and antibody in proliferation assays. The fusion protein had 70-fold more activity on the proliferation of T cells than the antibody (FIG. 9).

[0197] Because this antibody Ab has been shown to have potent activity in animal models of cancer immunotherapy, see, e.g., Melero et al., 1998, Cell Immunol. 190: 167-72; Melero et al., 1997 Nat. Med. 3: 682-85, this data indicates that the CSA-4-1BBL fusion protein will be a useful component of cancer vaccines, both as an adjuvant and as a vehicle to deliver TAAs to DCs.

example 3

Effect of a Biotinylated OVA / CSA-4-1-BBL Conjugate On CD8+ T Cells

[0198] Ovalbumin peptide (OVA) was biotinylated using a commercially available kit (Pierce Biotechnology, Rockford, Ill.). Biotinylated OVA was premixed in vitro with CSA-4-1BBL fusion protein for conjugation at various ratios and injected intraperitoneally into naïve C57BL / 6.SJL animals adoptively transferred with one million OT-1 T cells. Specifically, one million OT-I CD8+ T cells were labeled with CFSE and transferred into B6.SJL mice that were immunized with biotinylated ovalbumin (10 μg / injection) (“OVA”) and CSA-4-1BBL (1 μg / injection) mixed with biotinylated OVA (“41BBL+OVA”) or conjugated OVA-biotin / CSA-4-1BBL (“41BBL-OVA). (FIG. 10) The last panel of FIG. 10 (“41BBL-OVA*”) shows the response for 5 μg of CSA-4-1BBL conjugated to 10 μg biotinylated OVA. For controls, core streptavidin (“SA”) was used at equimolar level as CSA-4-1BBL.

[0199] As shown in FIG. 10, 4-1BBL / OVA conjugates generated a potent (73.5%)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
mean fluorescence intensityaaaaaaaaaa
MFIaaaaaaaaaa
Login to view more

Abstract

The invention provides conjugates comprising an immune co-stimulatory polypeptide and an antigen or infectious agent. The conjugates are useful for generating or enhancing an immune response against the antigen or infectious agent. The invention also provides immune cells modified with a conjuagte that are useful for generating or enhancing an immune response to an antigen or infectious agent. The invention also provides immunostimulatory moieties comprising an immune co-stimulatory polypeptide that are useful for stimulating an immune response. The invention also provides immunotherapy methods and methods of treating or preventing infections.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] The present application claims the benefit under 35 U.S.C. §119(e) of the filing dates of the following U.S. provisional applications: 60 / 748,177 (filed Dec. 8, 2005); 60 / 771,179 (Feb. 6, 2006); 60 / 799,643 (filed May 12, 2006); and 60 / 863,173 (filed Oct. 27, 2006). Each of the foregoing applications is incorporated by reference herein in its entirety.FIELD OF THE INVENTION [0002] The present invention generally relates to methods of generating or enhancing an immune response, including an immune response against an antigen, to compositions for effecting the methods, and to modified immune cells useful in such methods. BACKGROUND OF THE INVENTION [0003] Approaches directed to boosting a host's immune response to address diseases and conditions characterized by a deficiency in immunity or resolvable by a more aggressive immune response have been described. Exemplary diseases or conditions where such approaches may be advantageous include ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68C12P21/06
CPCC07K14/70532C12N2760/16134C12N5/0012C07K14/70575C12N2710/20034A61K39/0011A61K45/06A61K47/4833A61K47/48353A61K2039/5152A61K2039/5154A61K2039/5158A61K2039/55516A61K2039/6031B82Y5/00A61K38/00A61K39/12A61K2039/585A61K2039/625A61K2300/00A61K47/646A61K47/665A61P31/00A61P31/04A61P31/12A61P31/14A61P33/00A61P35/00A61P37/04Y02A50/30A61K47/50C07K14/705
Inventor SHIRWAN, HAVALELPEK, KUTLU G.YOLCU, ESMA S.
Owner UNIV OF LOUISVILLE RES FOUND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap